Dietary Fat Increases High Density Lipoprotein (HDL) Levels Both by Increasing the Transport Rates and Decreasing the Fractional Catabolic Rates of HDL Cholesterol Ester and Apolipoprotein (Apo) A-I

Presentation of a New Animal Model and Mechanistic Studies in Human Apo A-I Transgenic and Control Mice

Tony Hayek,* Yasushi Itô,* Neel Azrulan,* Roy B. Verdeny,† Katrinna Aalto-Setälä,* Annemarie Walsh,* and Jan L. Breslow* *Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York 10021-6399; and†Arizona Center on Aging, Tucson, Arizona 85719

Abstract

In humans, diets high in saturated fat and cholesterol raise HDL-cholesterol (HDL-C) levels. To explore the mechanism, we have devised a mouse model that mimics the human situation. In this model, HuAITg and control mice were studied on low fat (9% cal)-low cholesterol (57 mg/1,000 kcal) (chow) and high fat (41% cal)-high cholesterol (437 mg/1,000 kcal) (milk-fat based) diets. The mice responded to increased dietary fat by increasing both HDL-C and apo A-I levels, with a greater increase in HDL-C levels. This was compatible with an increase in HDL size observed by nondenaturing gradient gel electrophoresis. Turnover studies with doubly labeled HDL showed that dietary fat both increased the transport rate (TR) and decreased the fractional catabolic rate of HDL cholesterol ester (CE) and apo A-I, with the largest effect on HDL CE TR. The latter suggested that dietary fat increases reverse cholesterol transport through the HDL pathway, perhaps as an adaptation to the metabolic load of a high fat diet. The increase in apo A-I TR by dietary fat was confirmed by experiments showing increased apo A-I secretion from primary hepatocytes isolated from animals on the high fat diet. The increased apo A-I production was not associated with any increase in hepatic or intestinal apo A-I mRNA, suggesting that the mechanism of the dietary fat effect was posttranscriptional, involving either increased translatability of the apo A-I mRNA or less intracellular apo A-I degradation. The dietary fat-induced decrease in HDL CE and apo A-I fractional catabolic rate may have been caused by the increase in HDL particle size, as was suggested by our previous studies in humans. In summary, a mouse model has been developed and experiments performed to better understand the paradoxical HDL-raising effect of a high fat diet. (J. Clin. Invest. 1993. 91:1665–1671.) Key words: high density lipoprotein • high fat • turnover • particle size distribution • metabolism • apolipoprotein A-I • diet responsiveness

Introduction

In most societies today, there is a well-known inverse correlation between coronary heart disease risk and HDL cholesterol (HDL-C) levels (1–3). However, paradoxically, diets high in saturated fat and cholesterol, which increase atherosclerosis risk, raise HDL-C levels (4–9). To explore the mechanism for this phenomenon and perhaps gain greater insight into the role of HDL in heart disease, in a previous human metabolic study (9), we measured the turnover of the major HDL apolipoproteins, apo A-I and apo A-II, in 13 subjects consuming low fat (9% calories)-low cholesterol (40 mg/1,000 kcal) and high fat (42% calories)-high cholesterol (215 mg/1,000 kcal) diets. The dietary fat challenge increased HDL-C 40%, apo A-I 30% (both P < 0.001), with no change in apo A-II levels. The turnover studies indicated a 17% increase in apo A-I transport rate (TR) and a 10% decrease in apo A-I fractional catabolic rate (FCR). Individual changes in HDL-C levels correlated with changes in apo A-I TR (r = 0.79, P < 0.001) but not FCR (r = −0.04). This study suggested that dietary fat both increases the TR and decreases the FCR of apo A-I with perhaps a larger effect on the TR (9).

Since clinical studies do not allow further examination of how dietary fat influences apo A-I metabolism nor do they permit studies of HDL CE metabolism, in the current study, to pursue these questions, an animal model was created. Mice were used because of the availability of human apo A-I transgenic (HuAITg) lines (10, 11). These animals express significant amounts of human apo A-I in plasma, and for reasons not yet understood, they have greatly diminished mouse apo A-I levels (11–13). Accompanying this exchange of human for mouse apo A-I is a change from normal mouse HDL, which has a single major size distribution of HDL particles to human-like HDL characterized by two or more major size distributions, principally HDL3a and HDL2a (11–13). Thus, HuAITg mice might be a better model in which to study the dietary fat-HDL relationship.

As in the human metabolic study, mice were fed low fat (9% calories)-low cholesterol (57 mg/1,000 kcal) and high fat (41% calories), high cholesterol (437 mg/1,000 kcal) diets. In contrast to previously used high-fat-high cholesterol diets that have lowered HDL-C and apo A-I levels in some strains of mice

1. Abbreviations used in this paper: CE, cholesterol ester; FCR, fractional catabolic rate; GGE, gradient gel electrophoresis; HDL-C, HDL cholesterol; TR, transport rate.
(14), the dietary fat challenge raised HDL-C and apo A-I levels, as observed in humans (4–9), allowing detailed examination of the mechanism(s) for this dietary fat effect in the animal model.

**Methods**

Transgenic mice. One line of human apo A-I transgenic mice (line 179), which was previously described (10), was used. The line was created by microinjecting an 11.5-kb human apo A-I genomic fragment extending from 5.5 kb 5' to 3.8 kb 3' to the gene into F1 (C57BL/ 6J × CBA/J) fertilized eggs. The founder mouse was mated to F1s of the same genetic background, and transgenic offspring were similarly mated. Comparisons in metabolic studies were with nontransgenic litter mates. Whereas the endogenous mouse apo A-I gene is expressed equally in the liver and intestine, the human apo A-I transgene is expressed in the liver in this line of mice (10).

_Diets_. The mice were fed two contrasting diets. The low-fat-low cholesterol diet was rodent chow (no. 5001;Ralston-Purina, St. Louis, MO). Its composition was (wt/wt): 4.5% fat, 59.8% carbohydrate, 23.4% protein, 5.0% fiber, 7.3% minerals, added vitamins A, D, and E, and 0.02% cholesterol. Fats provided 9% of the calories, equally divided between saturated, monounsaturated, and polyunsaturated fats (kindly analyzed by Dr. Lisa Hudgins [15]), and there was 57 mg/1,000 kcal of cholesterol. The high-fat-high cholesterol diet was a milk-fat based diet made for us (TD88813; Teklad Premier Laboratory Diets, Madison, WI). Its composition was (wt/wt): 21.2% fat, 49.1% carbohydrate, 19.8% protein, 5.0% fiber, 3.5% minerals, 0.4% CaCO3, 1% vitamin mix, 0.004% antioxidant, and 0.2% cholesterol. Fats provided 41% of the calories, with 27% saturated, 12% monounsaturated, and 2% polyunsaturated, and there was 437 mg/1,000 kcal of cholesterol. The cholesterol content of both diets was verified by gas chromatography. The fat content of the high-fat-high cholesterol diet corresponds to the 50th percentile of American dietary intake observed in the Lipid Research Clinic Study and the 75th percentile of intake in the most recent National Health and Nutrition Examination Survey (16, 17).

_Blood and tissue sampling protocol_. Animals were placed in metabolic cages in animal rooms with alternating 12-h periods of light (7 a.m.–7 p.m.) and dark (7 p.m.–7 a.m.) with ad lib access to food and water. For blood sampling, mice were fasted overnight and the animals bled the next morning from the retroorbital plexus under methoxyflu- ran anesthesia. Blood was collected into a tube containing 6 μl of EDTA (0.5 M). Plasma was separated by centrifugation at 1,875 g for 15 min and kept at 4°C until analysis. Where indicated, fasted animals were subjected to liver biopsy through a midline incision under anesthesia with 2.5% Avertin (0.02 ml/g body wt). The liver tissue (50–100 mg) was frozen immediately in liquid nitrogen and stored at −70°C. At the end of each study diet, the animals were fasted overnight and anesthetized with 2.5% Avertin. The liver and total small intestine were obtained, frozen immediately, and stored as above.

_Plasma HDL-C and apo A-I analyses_. HDL-C levels were determined by measuring cholesterol either in the d > 1.063 g/ml infranatant after airfuge ultracentrifugation, as previously described (10), or in the supernatant after precipitation of the other lipoproteins by dextran sulfate. The latter involved adding 11 μl of dextran sulfate Mg2+ solution (10 g/liter dextran sulfate, mol wt 50,000, 0.5 mol/liter Mg2+, buffered (no. 352-3; Sigma Immunonochemicals, St. Louis, MO) to 60 μl of plasma. This procedure was validated by immunochemical methods by showing that it did not precipitate apo A-I, but precipitated 96% of apo B. The particular method used for HDL-C determination in a given experiment is indicated. Cholesterol was determined enzymati- cally using reagents (no. 236691; Boehringer). In the HDL fraction, free cholesterol and total cholesterol (after saponification) were measured by gas chromatography with caprostanol as an internal standard. The cholesterol ester (CE) was taken as the difference between the two. Mouse apo A-I levels were quantified by rocket immunoelectrophoresis using a polyclonal anti–mouse apo A-I antibody prepared in cyno- molus monkeys (generously provided by Dr. George Melchior, Up- john Company, Kalamazoo, MI) as previously described (10, 12, 13). Human apo A-I levels were measured by enzyme-linked immunobesorbt assay using a polyclonal goat anti–human apo A-I antibody, which was a gift from Dr. Peter Herbert, Miriam Hospital (Providence, RI) as previously described (10, 18). There was essentially no cross- species reactivity for either antibody.

_In vivo HDL turnover studies_. HDL doubly labeled in its apo A-I and cholesterol ester moieties was prepared as previously described (12, 13, 19–21). We previously showed that human and mouse apo A-I have the same rate of disappearance from the plasma of HuA1g and control mice (10). Therefore, turnover studies in the current experiments were done only with radioiodinated human apo A-I. HDL CE was labeled with [3H]cholesterol oleoyl ether that had been dissolved in intralipid and transferred into HDL by CETP from d > 1.25 g/ml rabbit plasma (12, 13, 21). Mice were injected in the femoral vein with doubly labeled HDL (2–4 μg of [13]H) human apo A-I and 100,000–200,000 dpm of [3H]cholesterol oleoyl ether). The injected HDL mass was < 5% of the mouse HDL pool (12, 21). Blood (50 ml) was taken from the retroorbital plexus under methoxyflurane anesthesia at 10 min, 90 min, 3 h, 8 h, and 24 h for determination of radioactivity. The FCRs for apo A-I and HDL CE were calculated from the plasma decay curves of [13]H apo A-I and [3H]cholesterol oleoyl ether assuming a two-pool model by the Matthews method (22).

_HDL particle size determination_. HDL particle size distribution was determined by nondenaturing gradient gel electrophoresis (GGE) as previously described (23, 24). In a 175-μl airfuge tube, 40 μl of plasma was adjusted to density 1.21 g/ml with 1.35 g/ml KBr, and this was overlayed with 50 μl of 1.21 g/ml KBr (1 mM EDTA). After ultracentrifugation at 100,000 g for 5 h (Airfuge, Beckman), 30 μl was aspirated from the top of the tube and electrophoresed in nondenaturating 4–30% polyacrylamide gradient gels (PA4 A/30; Pharmacia LKB, Piscataway, NJ) for 20 min at 70 V and then for 18–24 h at 125 V. Gels were fixed, stained, destained, and scanned as previously described (24). Scans were analyzed by Gaussian modeling and Stokes' radii of HDL particles determined by comparing migration distances to those of proteins of known size (24).

_In vitro apo A-I production_. Apo A-I production was determined in primary hepatocytes from mice fed the low-fat-low cholesterol and high-fat-high cholesterol diets. Mice were weaned and then fed the diets for 4 wk. Animals were fasted overnight, anesthetized with 5% sodium pentobarbital, and hepatocytes prepared by minor modifications of the method described by Sparks (25). The portal vein was cannulated and the liver was first perfused with a calcium-free isotonic buffer at 37°C for 10–15 min, and then perfused with a buffer containing 5 mM CaCl2 and 0.075% (wt/vol) collagenase (Boehringer Mannheim) for 30 min. After perfusion, the liver was gently disaggregated and the cells suspended in calcium-free buffer. The cells were washed with PBS and M199 (Sigma Immunonochemicals), and dead cells were separated by centrifugation in 50% colloidal polyvinyl pyrrolidone–coated silica (percoll; Sigma Immunonochemicals). Cell viability was assured by trypan blue staining and 500,000 live cells were plated on a 35-mm plate coated with poly-d-lysine. The culture medium was changed after 4 h incubation at 37°C. The next day, the cells were washed with M199, and fresh culture medium containing 100 μg/ml of [35]methionine was added and the cells incubated for 40, 60, 90, and 120 min at 37°C. After incubation, the medium was removed, the cells were washed twice with PBS, and then solubilized with 0.1 N NaOH. Cell protein was determined using the detergent-compatible protein assay (BioRad Laboratories, Richmond, CA) using BSA as a standard. 300 μl medium from each plate was used for immunoprecipitation using a mono-spe- cific goat anti–human apo A-I antibody that does not bind to mouse apo A-I. Briefly, an equal volume of protein-A binding buffer (Pierce Chemical Co., Rockford, IL) was mixed with the medium in a 1:5 ml Eppendorf tube. To this was added 15 μl anti–human A-I antisera, and the tubes were placed on a rocker at 4°C for 16 h. The next day, 15 μl of rabbit anti–goat IgG (Pierce Chemical Co.) was added and the tubes were incubated for 2 h at 4°C. 60 μl of a 20% protein-A Sepharose
Table I. Effects of Diet on HDL Cholesterol and Apo A-I Levels

<table>
<thead>
<tr>
<th>Mice</th>
<th>HDL-C* (mg/dl)</th>
<th>Percent increase</th>
<th>Human Apo A-I (mg/dl)</th>
<th>Percent increase</th>
<th>Mouse Apo A-I (mg/dl)</th>
<th>Percent increase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td></td>
<td>Before</td>
<td>After</td>
<td></td>
</tr>
<tr>
<td>HuAITg (n = 5)</td>
<td>103 ± 7</td>
<td>170 ± 16a</td>
<td>65%</td>
<td>244 ± 7</td>
<td>345 ± 16a</td>
<td>41%</td>
</tr>
<tr>
<td>Controls (n = 6)</td>
<td>51 ± 2</td>
<td>78 ± 3a</td>
<td>53%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>HuAITg (n = 6)</td>
<td>89 ± 4</td>
<td>87 ± 5</td>
<td>—</td>
<td>233 ± 24</td>
<td>233 ± 24</td>
<td>—</td>
</tr>
</tbody>
</table>

* HDL-C levels were determined by measuring cholesterol in the d > 1.063 g/ml infranatant after airfuge ultracentrifugation.

1 P = 0.059  
2 P < 0.05  
3 P < 0.01  
4 P < 0.005  
5 Significance of the difference between the end and the beginning of the experimental period.

Dietary Fat Increases High Density Lipoprotein Levels 1667
ters (Fig. 1 A). The patterns obtained by GGE analysis for several HuAITg mice on low fat-low cholesterol (n = 6) and high fat-high cholesterol (n = 5) diets were scanned individually and analyzed by Gaussian modeling (24). The results for each group of animals were averaged and the data were presented in Fig. 1 B. It can be seen that the high fat-high cholesterol diet caused a relative increase only in the HDL subfractions of mean particle diameter ≥ 11.0 nm. Thus, a high fat-high cholesterol diet increases HDL size in both HuAITg and control mice, which is compatible with the greater increase in HDL-C compared to apo A-I, as shown in Tables I and II.

The HDL turnover studies showed that the high fat-high cholesterol diet increased the apo A-I TR. In the HuAITg mice human apo A-I is only synthesized in the liver, suggesting that this increase in apo A-I TR was caused by an increase in hepatic secretion of apo A-I. To confirm this, primary hepatocytes from HuAITg mice fed low fat-low cholesterol or high fat-high cholesterol diets were studied in an in vitro labeling experiment. As shown in Fig. 2, radiolabeled human apo A-I was secreted 40% faster from hepatocytes prepared from the animals on the high fat-high cholesterol diet relative to those prepared from animals on the low fat-low cholesterol diet. A similar effect was observed for mouse apo A-I secretion (data not shown). Thus, a high fat-high cholesterol diet increases apo A-I secretion from the liver.

The mechanism for increased hepatic apo A-I secretion was explored further. Liver and intestinal apo A-I mRNA levels were quantified by solution hybridization/RNase protection assay in the HuAITg and control mice on the low fat-low cholesterol and high fat-high cholesterol diets. As shown in Table III, the high fat-high cholesterol diet had no significant effect on hepatic (human or mouse) or intestinal (mouse) apo A-I mRNA levels. Thus, dietary fat appears to exert its effect on apo A-I production at a posttranscriptional level. It is also noteworthy that hepatic and intestinal mouse apo A-I mRNA levels are comparable in HuAITg and control mice, in spite of the large reduction in plasma mouse apo A-I levels in the transgenic animals.

### Discussion

Diet high in saturated fat and cholesterol increase the risk of coronary heart disease in humans, yet they raise HDL-C levels (4–9). To study this paradoxical phenomenon a mouse model was created. In this model, animals were studied on a low fat-low cholesterol chow diet and a high fat-high cholesterol Western type diet and dietary fat was shown to increase HDL-C

---

**Table II. Effects of Diet on HDL Metabolism**

<table>
<thead>
<tr>
<th>Mice</th>
<th>HDL-C* (mg/dl)</th>
<th>HDL CE FCR (pools/h)</th>
<th>HDL CE TR (U)</th>
<th>Apo A-I (mg/dl)</th>
<th>Apo A-I FCR (pools/h)</th>
<th>Apo A-I TR (U)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chow diet</td>
<td>103±7</td>
<td>0.110±0.003</td>
<td>8.4±0.7</td>
<td>326±20</td>
<td>0.106±0.009</td>
<td>34.4±3.5</td>
</tr>
<tr>
<td>High fat diet</td>
<td>220±25</td>
<td>0.079±0.009</td>
<td>13.5±0.2</td>
<td>570±40</td>
<td>0.078±0.008</td>
<td>44.3±4.6</td>
</tr>
<tr>
<td>Control (n = 3)</td>
<td>54±3</td>
<td>0.182±0.009</td>
<td>7.3±0.2</td>
<td>168±12</td>
<td>0.105±0.005</td>
<td>17.6±1.1</td>
</tr>
<tr>
<td>High fat diet</td>
<td>103±5&quot;</td>
<td>0.137±0.005&quot;</td>
<td>10.7±0.8&quot;</td>
<td>275±5&quot;</td>
<td>0.079±0.003&quot;</td>
<td>21.8±0.1&quot;</td>
</tr>
</tbody>
</table>

* HDL-C levels were determined by measuring cholesterol in the supernatant after precipitation of the other lipoproteins by dextran sulfate.

\[ P < 0.05 \]

\[ P < 0.005 \] compared to the chow diet.

\[ P < 0.001 \]
levels as it does in humans (4—9). Metabolic turnover studies indicated that the high fat-high cholesterol diet decreased the FCR and increased the TR of HDL CE. The dietary effect was greatest on the HDL CE TR (≈ 60% increase). This is a novel observation that may have significant implications, since HDL is thought to be involved in reverse cholesterol transport (1—3, 29, 30). The current study suggests that the dietary fat—induced increase in HDL-C levels may be an adaptive mechanism reflecting the need for increased flux (HDL CE TR) through the HDL pathway required by the metabolic load of a high fat—high cholesterol diet. In our previous metabolic study in humans, HDL-C levels increased 40% when switching from a 10 to a 40% fat diet (9). However, there was a wide range of HDL-C response, from 7 to 68%. It would have been fascinating to observe whether this range of responses of HDL-C levels correlates with differences among people in their ability to increase the flux of HDL CE (HDL CE TR). Humans who fail to respond adequately to a dietary challenge by raising their HDL-C levels and HDL CE TR may be at increased risk of atherosclerosis. Unfortunately, it has not been possible to easily measure HDL CE turnover in humans to study this question (31).

In the mouse model the high fat—high cholesterol diet compared to the low fat—low cholesterol diet was also shown to increase apo A-I levels, decrease apo A-I FCR and increase apo A-I TR. These results are quite comparable to those we previously obtained in humans with a similar dietary change (9). Other clinical investigators, utilizing different dietary protocols, have had different results. Blum studied three females on an extremely low fat liquid formula diet and on a high fat diet, and found a 62% increase in HDL-C levels, which he ascribed to a 32% decrease in HDL apolipoprotein FCR (6). Shepherd studied four males on a 40% fat intake of a polynsaturated/saturated fat ratio of 4 and 0.25, and found a 48% increase in HDL-C accounted for by a 35% increase in apo A-I TR (7). In animal studies, Quig reported in rabbits that a sixfold increase in saturated fat intake was associated with a twofold increase in HDL apolipoprotein TR without any change in FCR (32). Sorci-Thomas has reported in nonhuman primates on a high cholesterol diet that a change in the polynsaturated/saturated fat ratio from 2.2 to 0.3 caused a 19% increase in apo A-I levels associated with a 23% increase in hepatic synthesis of apo A-I and a 28% increase in hepatic apo A-I mRNA, with no change in intestinal apo A-I mRNA (33). Thus, our own studies in humans and mice and those of others pretty consistently indicate a major effect of dietary fat on the apo A-I TR.

The measurement of apo A-I TR by turnover studies suggests that dietary fat increases hepatic or intestinal production of apo A-I. The line of HuAITg mice used in these experiments produces human apo A-I only in the liver (10). Since dietary fat caused an equal percent increase of human and mouse apo A-I in these mice, it suggests that the effect is exerted mainly on hepatic apo A-I production. Increased hepatic production of apo A-I was corroborated by in vitro labeling studies in which primary liver cell cultures from animals fed the high fat—high cholesterol diet showed increased apo A-I secretion. Srivastava et al. (34) have also shown, using liver slices, that the hepatic production of mouse apo A-I is increased in mice fed a high

---

**Table III. Effects of Diet on Hepatic and Intestinal Apo A-I mRNA Levels**

<table>
<thead>
<tr>
<th>Mice</th>
<th>Human Apo A-I mRNA</th>
<th>Mouse Apo A-I mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Liver</td>
<td>Before</td>
</tr>
<tr>
<td>HuAITg (n = 5)</td>
<td></td>
<td>pg/ug total RNA</td>
</tr>
<tr>
<td>High fat diet</td>
<td>254±2</td>
<td>253±2</td>
</tr>
<tr>
<td>Controls (n = 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High fat diet</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>HuAITg (n = 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low fat diet</td>
<td>250±3</td>
<td>240±15</td>
</tr>
</tbody>
</table>

There were no significant differences in hepatic apo A-I mRNA before and after the diet, nor were there any differences in intestinal apo A-I mRNA between HuAITg mice on high fat and low fat diets.

---

*Figure 2. Effect of the high fat diet on human apo A-I secretion from transgenic mouse primary hepatocytes. HuAITg mice were fed a high fat—high cholesterol diet or a low fat—low cholesterol diet for 4 wk. Primary mouse hepatocytes were then prepared from these animals as described in Methods. These cells were incubated with serum-free medium containing 100 μCi/ml [35S]methionine for the indicated times. An aliquot of conditioned medium from each plate was then immunoprecipitated using an anti—human apo A-I antibody that specifically recognizes only human apo A-I. The immuno-complex was washed and subjected to SDS-PAGE analysis. Gels were then dried and autoradiographed. A representative gel film is shown in the inset. Regions on each gel that corresponded to the apo A-I bands (inset) were excised from the gel and subjected to scintillation counting. Three different gels, each derived from three different sets of dishes were used in each analysis. The experiment shown was performed several (three) times with similar results. Error bars represent SEM (n = 3).*
fat-high cholesterol diet. To further localize how dietary fat is acting, apo A-1 mRNA levels were measured in tissues from animals on the two contrasting diets and no differences were found. Thus, the effect of dietary fat on apo A-I production is posttranscriptional and could involve increased translatability of the apo A-I mRNA or decreased intracellular degradation of the apo A-I protein. Go et al. have shown increased translatability of rat intestinal apo A-I mRNA with chronic feeding of 2% cholesterol and 0.1% propylthiouracil (35). Davis and others have shown that apo B secretion from hepatocytes is regulated by changes in intracellular degradation (36). Further studies will be necessary to determine exactly the mechanism of the dietary fat effect on apo A-I production.

In humans, a high fat diet causes an increase in the HDL-C to apo A-I ratio and an increase in HDL size (4–9, 37). This also occurred in both the HuAIG and control mice, as shown by chemical analysis and gradient gel electrophoresis. In previous studies in humans, we showed that apo A-I FCR was inversely correlated with HDL size and in a multivariate model HDL size was the best predictor of apo A-I FCR of all the relevant variables tested (38, 39). Thus, in the mouse model the effect of dietary fat on apo A-I and even HDL CE FCR might be mediated by the change in HDL size caused by the diet. It has been suggested that large HDL particles are less easily catabolized, such as through glomerular filtration of apo A-I or liver uptake of HDL particles (40), and this may account for the decrease in FCR.

Previous fat feeding studies in mice have involved toxic diets, such as ones containing 1.25% cholesterol, 15% fat, and the unusual constituent 0.5% cholic acid (14, 35, 41). These diets did not increase HDL-C levels, but rather produced a strain-dependent decrease in HDL-C levels. This is contrary to what one sees in humans placed on a high fat diet and raises questions about the relevance of such diets to the human experience. The current manuscript presents a high fat mouse diet that mimics the human experience and has allowed examination of the mechanism whereby dietary fat influences HDL metabolism.

Acknowledgments

The authors would like to thank Dr. Tova Chajek-Shaul for her expert consultation and for her help in performing some of the turnover studies. We would also like to acknowledge the assistance of Ethel O. Kouba, Ph.D., and Emilio H. Moriguchi, M.D., Ph.D., at the Bowman Gray School of Medicine (Winston-Salem, NC).

This work was supported by J. L. Breslow’s National Institutes of Health grants R01 HL-32435, R01 HL-33714, and P01 CA29502, the Calder Foundation, and R. B. Verdery’s National Institutes of Health grant K01 AG00414.

References


